GW Pharmaceuticals PLC Company Profile (NASDAQ:GWPH)

About GW Pharmaceuticals PLC (NASDAQ:GWPH)

GW Pharmaceuticals PLC logoGW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the Company's commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:GWPH
  • CUSIP: N/A
  • Web:
  • Market Cap: $2.81729 billion
  • Outstanding Shares: 25,325,000
Average Prices:
  • 50 Day Moving Avg: $107.97
  • 200 Day Moving Avg: $107.72
  • 52 Week Range: $92.65 - $136.95
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -17.45
  • P/E Growth: 0.37
Sales & Book Value:
  • Annual Revenue: $10.25 million
  • Price / Sales: 273.78
  • Book Value: $16.46 per share
  • Price / Book: 6.73
  • EBITDA: ($171,620,000.00)
  • Net Margins: -1,384.41%
  • Return on Equity: -28.80%
  • Return on Assets: -25.20%
  • Debt-to-Equity Ratio: 0.02%
  • Current Ratio: 10.39%
  • Quick Ratio: 10.26%
  • Average Volume: 358,798 shs.
  • Beta: 2.65
  • Short Ratio: 9.67

Frequently Asked Questions for GW Pharmaceuticals PLC (NASDAQ:GWPH)

What is GW Pharmaceuticals PLC's stock symbol?

GW Pharmaceuticals PLC trades on the NASDAQ under the ticker symbol "GWPH."

How were GW Pharmaceuticals PLC's earnings last quarter?

GW Pharmaceuticals PLC (NASDAQ:GWPH) posted its quarterly earnings results on Monday, August, 7th. The company reported ($2.07) EPS for the quarter, missing the consensus estimate of ($1.73) by $0.34. The business had revenue of $3.14 million for the quarter, compared to analysts' expectations of $2.10 million. GW Pharmaceuticals PLC had a negative return on equity of 28.80% and a negative net margin of 1,384.41%. During the same period last year, the business posted ($0.05) earnings per share. View GW Pharmaceuticals PLC's Earnings History.

When will GW Pharmaceuticals PLC make its next earnings announcement?

GW Pharmaceuticals PLC is scheduled to release their next quarterly earnings announcement on Monday, December, 4th 2017. View Earnings Estimates for GW Pharmaceuticals PLC.

Where is GW Pharmaceuticals PLC's stock going? Where will GW Pharmaceuticals PLC's stock price be in 2017?

7 brokerages have issued twelve-month price targets for GW Pharmaceuticals PLC's stock. Their predictions range from $61.00 to $208.00. On average, they anticipate GW Pharmaceuticals PLC's share price to reach $144.57 in the next twelve months. View Analyst Ratings for GW Pharmaceuticals PLC.

What are analysts saying about GW Pharmaceuticals PLC stock?

Here are some recent quotes from research analysts about GW Pharmaceuticals PLC stock:

  • 1. According to Zacks Investment Research, "GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. " (7/24/2017)
  • 2. Maxim Group analysts commented, "GW pharmaceuticals announced publication of data from the P3 study of Epidiolex (oral CBD, cannabidiol) in pediatric Dravet Syndrome in The New England Journal of Medicine (NEJM)." (5/25/2017)
  • 3. Cantor Fitzgerald analysts commented, "NDA Filing Expected Mid-2017. GWPH expects to complete its filing in the U.S. shortly and noted two key portions in progress: 1) an integrated safety analysis of over 1,500 treated patients from clinical studies and the expanded access program, and 2) manufacturing data from the company’s manufacturing processes, including scaled materials. These elements will be the two determining factors of the timing of the NDA submission, which is expected in the middle of the year. Following the U.S. submission, GW expects to submit its MAA filing in 2H17 and plans to meet with the EMA in the near term. Pre-commercialization Activities Intensify. Greenwich Biosciences, the U.S. subsidiary of GW, is progressing with a pre-commercial strategy of expanding its team for the drug launch of Epidiolex. GW guided for a commercial team consisting of 15 medical-science liaisons by the end of 2017 and a sales force of 50-60 sales representatives to reach 4,000-5,000 targeted U.S. physicians. In addition, the company has begun to engage payors on awareness of patient need, Epidiolex, and pricing. We believe these efforts will set a meaningful foundation for Epidiolex’s commercial launch, which we estimate will initiate in 2018. Model Update. Following F2Q17 financial results, we have updated our model to reflect recent quarterly results and future expectations of operational expenditures." (5/9/2017)

Who are some of GW Pharmaceuticals PLC's key competitors?

Who are GW Pharmaceuticals PLC's key executives?

GW Pharmaceuticals PLC's management team includes the folowing people:

  • Geoffrey W. Guy, Executive Chairman of the Board
  • Justin Gover, Chief Executive Officer, Director
  • Adam David George, Chief Financial Officer, Company Secretary, Director
  • Christopher John Tovey, Chief Operating Officer, Executive Director
  • Julian S. Gangolli, Executive Director
  • James Julian Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director
  • Cabot Brown, Non-Executive Independent Director
  • Thomas Gerard Lynch, Non-Executive Independent Director

How do I buy GW Pharmaceuticals PLC stock?

Shares of GW Pharmaceuticals PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GW Pharmaceuticals PLC's stock price today?

One share of GW Pharmaceuticals PLC stock can currently be purchased for approximately $110.81.

MarketBeat Community Rating for GW Pharmaceuticals PLC (NASDAQ GWPH)
Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  340 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  468
MarketBeat's community ratings are surveys of what our community members think about GW Pharmaceuticals PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for GW Pharmaceuticals PLC (NASDAQ:GWPH) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $144.57 (30.47% upside)
Consensus Price Target History for GW Pharmaceuticals PLC (NASDAQ:GWPH)
Price Target History for GW Pharmaceuticals PLC (NASDAQ:GWPH)
Analysts' Ratings History for GW Pharmaceuticals PLC (NASDAQ:GWPH)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/6/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral -> Neutral$124.00N/AView Rating Details
10/2/2017Cantor FitzgeraldReiterated RatingOverweight$208.00MediumView Rating Details
10/2/2017Cowen and CompanyReiterated RatingOutperform$165.00MediumView Rating Details
10/2/2017Leerink SwannReiterated RatingOutperform$160.00 -> $153.00MediumView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$154.00MediumView Rating Details
8/8/2017Maxim GroupDowngradeBuy -> Hold$61.00HighView Rating Details
2/7/2017Piper Jaffray CompaniesSet Price TargetBuy$147.00N/AView Rating Details
9/25/2016Morgan StanleyBoost Price TargetOverweight$152.00 -> $160.00N/AView Rating Details
8/26/2016Numis Securities LtdUpgradeSell -> HoldN/AView Rating Details
7/18/2016Bank of America CorporationReiterated RatingBuy$153.00N/AView Rating Details
6/27/2016Janney Montgomery ScottInitiated CoverageSell$40.00N/AView Rating Details
3/14/2016Roth CapitalBoost Price TargetBuy$130.00 -> $160.00N/AView Rating Details
(Data available from 10/18/2015 forward)


Earnings History for GW Pharmaceuticals PLC (NASDAQ:GWPH)
Earnings by Quarter for GW Pharmaceuticals PLC (NASDAQ:GWPH)
Earnings History by Quarter for GW Pharmaceuticals PLC (NASDAQ GWPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/20176/30/2017($1.73)($2.07)$2.10 million$3.14 millionViewListenView Earnings Details
5/9/20173/31/2017($1.50)($1.70)$2.07 million$2.04 millionViewListenView Earnings Details
2/7/2017Q117($1.35)($0.77)$1.85 million$2.54 millionViewListenView Earnings Details
12/5/2016Q416($1.48)($0.89)$2.85 million$2.16 millionViewListenView Earnings Details
2/10/2016Q116($1.53)($0.10)$4.61 million$5.40 millionViewListenView Earnings Details
12/7/2015Q415($1.38)($0.85)$15.00 million$5.60 millionViewN/AView Earnings Details
8/6/2015Q315($1.30)($1.60)$12.82 million$13.55 millionViewN/AView Earnings Details
5/11/2015Q215($1.23)($0.58)$11.38 million$9.43 millionViewListenView Earnings Details
2/4/2015Q115($0.91)($0.26)$12.12 million$12.40 millionViewN/AView Earnings Details
12/2/2014Q414($0.46)$0.02$9.15 million$12.03 millionViewN/AView Earnings Details
8/6/2014Q314($0.62)($0.66)$12.88 million$13.00 millionViewN/AView Earnings Details
5/7/2014Q114($0.30)$0.49$12.48 million$12.55 millionViewN/AView Earnings Details
2/4/2014Q413($0.34)($0.02)$11.54 million$7.49 millionViewN/AView Earnings Details
11/19/2013Q4($0.19)($0.29)ViewListenView Earnings Details
8/5/2013Q313($0.11)$0.02$10.71 million$11.04 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for GW Pharmaceuticals PLC (NASDAQ:GWPH)
2017 EPS Consensus Estimate: ($8.16)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.80)($1.80)($1.80)
Q2 20171($1.98)($1.98)($1.98)
Q3 20172($2.34)($2.18)($2.26)
Q4 20171($2.12)($2.12)($2.12)
(Data provided by Zacks Investment Research)


Dividend History for GW Pharmaceuticals PLC (NASDAQ:GWPH)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for GW Pharmaceuticals PLC (NASDAQ:GWPH)
No insider trades for this company have been tracked by


Headline Trends for GW Pharmaceuticals PLC (NASDAQ:GWPH)
Latest Headlines for GW Pharmaceuticals PLC (NASDAQ:GWPH)
DateHeadline logo Analysts Expect GW Pharmaceuticals PLC (GWPH) to Post -$1.39 EPS - October 18 at 12:12 AM logoFuture Legal Cannabis Sales Projected to Rise - PR Newswire (press release) - October 16 at 9:01 PM logoGW Pharmaceuticals PLC (GWPH) Receives Consensus Rating of "Buy" from Analysts - October 12 at 12:48 AM logoGW Pharmaceuticals PLC (GWPH) Receives Neutral Rating from Goldman Sachs Group, Inc. (The) - October 6 at 8:34 PM logoThis Potential Billion-Dollar Marijuana-Based Drug Suddenly Finds Itself in Deep Trouble - October 6 at 8:47 AM logoZogenix - Share Offering And Double Top Reversal - October 4 at 1:46 PM logoWhat Do Zogenix Drug Study Results Mean For GW Pharmaceuticals' Epidiolex? - Benzinga - October 3 at 9:20 AM logoHow Risky Is GW Pharmaceuticals Stock After Zogenix's Big News? - October 3 at 9:19 AM logoZogenix Stock Nears 7-Year High On Excitement Over Epilepsy Drug - October 2 at 6:50 PM logoGW Pharmaceuticals PLC (GWPH) Rating Reiterated by Cowen and Company - October 2 at 1:56 PM logoGW Pharmaceuticals PLC (GWPH) Stock Rating Reaffirmed by Cantor Fitzgerald - October 2 at 1:56 PM logoDecember 15th Options Now Available For GW Pharmaceuticals (GWPH) - October 2 at 1:49 PM logoETFs with exposure to GW Pharmaceuticals Plc : October 2, 2017 - October 2 at 1:49 PM logoGW Pharmaceuticals PLC (GWPH) Price Target Cut to $153.00 by Analysts at Leerink Swann - October 2 at 10:16 AM logo$2.61 Million in Sales Expected for GW Pharmaceuticals PLC (GWPH) This Quarter - October 1 at 11:42 AM logoPre-Open Movers 09/29: (ZGNX) (VERI) (ROKU) Higher; (GWPH) (PRTA) (GLYC) Lower (more...) - September 29 at 4:39 PM logoZogenix Soars After Epilepsy Drug Meets Primary Endpoint -Biotech Movers - September 29 at 10:55 AM logoGW Pharmaceuticals (GWPH) Shares Cross Above 200 DMA - September 28 at 8:24 PM logoMedical Cannabis Companies Leverage Biosynthesis to Boost Drug Development - September 26 at 11:21 AM logoCan You Guess What Sears, GameStop, Spirit Airlines, Tootsie Roll, and Papa John's All Have in Common? - September 22 at 1:11 PM logoETFs with exposure to GW Pharmaceuticals Plc : September 22, 2017 - September 22 at 1:11 PM logoGW Pharmaceuticals PLC (GWPH) Given Average Recommendation of "Buy" by Brokerages - September 17 at 12:52 AM logoMontel Williams' Battle With Multiple Sclerosis And The Miracle Of Medical Marijuana - September 15 at 8:00 PM logoInvestors' Biggest Worry About GW Pharmaceuticals Could Be the Biotech's Ace in the Hole - September 14 at 8:01 PM logo Brokerages Anticipate GW Pharmaceuticals PLC (GWPH) Will Announce Quarterly Sales of $2.61 Million - September 12 at 3:56 PM logoETFs with exposure to GW Pharmaceuticals Plc : September 12, 2017 - September 12 at 1:27 AM logoCorporate News Blog - Leadership Change in Novartis as CEO Jimenez to Retire in 2018; Vasant Narasimhan Named His Successor - September 6 at 7:18 PM logoGW Pharmaceuticals to Present at Upcoming Investor Conferences ... - GlobeNewswire (press release) - September 6 at 4:04 AM logoGW Pharmaceuticals to Present at Upcoming Investor Conferences - September 6 at 4:04 AM logoGW Pharmaceuticals PLC (GWPH) & Paratek Pharmaceuticals (PRTK) Head-To-Head Survey - September 2 at 10:28 AM logoETFs with exposure to GW Pharmaceuticals Plc : August 31, 2017 - August 31 at 7:13 PM logoWhat You Need to Know About the 3 Kinds of Marijuana Stocks - August 27 at 6:16 PM logoGW Pharmaceuticals Plc :GWPH-US: Earnings Analysis: Q3, 2017 By the Numbers : August 24, 2017 - August 25 at 6:28 AM logoGW Pharmaceuticals PLC (GWPH) Given Average Recommendation of "Buy" by Analysts - August 23 at 12:30 AM logoEdison Issues Update on GW Pharmaceuticals (GWPH) - August 22 at 7:52 PM logoGW Pharmaceuticals: Buy The Dip - Seeking Alpha - August 20 at 5:41 PM logoWhat's Difference Between Zynerba, GW Pharma's Epilepsy Drugs ... - Benzinga - August 19 at 12:10 AM logoGW Pharmaceuticals PLC- ADR (GWPH) Stock Is High-Risk, High Reward - - August 19 at 12:10 AM logoWhat's The Difference Between Zynerba and GW Pharma's Epilepsy Drugs? - August 18 at 7:08 PM logoGW Pharmaceuticals PLC- ADR (GWPH) Stock Is High-Risk, High Reward - August 18 at 2:18 PM logoZynerba's Pain Could Be GW Pharmaceuticals' Gain - August 16 at 7:22 PM logoGW Pharmaceuticals PLC (GWPH) Earns Outperform Rating from Analysts at Evercore ISI - August 16 at 6:26 PM logo2 Marijuana Stocks That Turned $10,000 Into $125,000 and $300,000, Respectively - August 11 at 7:48 PM logoFY2017 Earnings Forecast for GW Pharmaceuticals PLC Issued By Leerink Swann (NASDAQ:GWPH) - August 10 at 9:10 AM logoInvestor Network Invites You to the GW Pharmaceuticals Third Quarter 2017 Earnings Conference Call and Webcast Live on Monday, August 7, 2017 - August 9 at 5:11 AM logoInvestor Network: GW Pharmaceuticals PLC to Host Earnings Call - August 9 at 5:11 AM logoGW Approaches Crunch Time - Seeking Alpha - August 8 at 7:04 PM logoThe 1 Word in GW Pharmaceuticals' Q3 Update That Disappointed Investors - August 8 at 7:03 PM logoIs GW Pharma Now The Future Of Cannabis-Based Drugs? - August 8 at 10:47 AM logoCantor Fitzgerald Reiterates $208.00 Price Target for GW Pharmaceuticals PLC (GWPH) - August 8 at 10:06 AM



GW Pharmaceuticals PLC (GWPH) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.